Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
SOHONOS (PALOVAROTENE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
SOHONOS
NDA
Get alerts
PALOVAROTENE | N215559 | IPSEN BIOPHARMACEUTICALS INC
5 strengths
9 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
9 unique patents, 2 exclusivities by expiration date
All strengths
1MG
1.5MG
2.5MG
5MG
10MG
Active (9)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
Today
9314439
Aug. 31, 2031
9789074
Aug. 31, 2031
10292954
Aug. 31, 2031
10864194
Jun. 8, 2037
11622959
Jun. 8, 2037
12023312
Aug. 31, 2031
12138245
Jun. 8, 2037
12201614
Jun. 8, 2037
12458626
Jun. 8, 2037
NCE
Aug. 16, 2028
ODE-439
Aug. 16, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (5)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 1MG
RLD
9 patents
2 exclusivities
▴
CAPSULE;ORAL | Approved: Aug 16, 2023
Patents (9)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9314439
Aug 31, 2031
—
—
—
U-3676
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
—
9789074
Aug 31, 2031
—
—
—
U-3676
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
—
10292954
Aug 31, 2031
—
—
—
U-3676
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
—
10864194
Jun 8, 2037
—
—
—
U-3676
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
—
11622959
Jun 8, 2037
—
—
—
U-3676
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
—
12023312
Aug 31, 2031
—
—
—
U-3966
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA
—
12138245
Jun 8, 2037
—
—
—
U-4031
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA
—
12201614
Jun 8, 2037
—
—
—
U-4031
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA
—
12458626
Jun 8, 2037
—
—
—
U-3676
REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
—
Exclusivities (2)
Code
Date
Status
NCE
Aug 16, 2028
Active
ODE-439
Aug 16, 2030
Active
#002 — 1.5MG
RLD
9 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Aug 16, 2023
#003 — 2.5MG
RLD
9 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Aug 16, 2023
#004 — 5MG
RLD
9 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Aug 16, 2023
#005 — 10MG
RLD
9 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Aug 16, 2023